| |  Online-Ressource |
|---|
| Verfasst von: | Kasper, Bernd [VerfasserIn]  |
|---|
| | Pink, Daniel [VerfasserIn] |
|---|
| | Rothermundt, Christian [VerfasserIn] |
|---|
| | Richter, Stephan [VerfasserIn] |
|---|
| | Augustin, Marinela [VerfasserIn] |
|---|
| | Kollar, Attila [VerfasserIn] |
|---|
| | Kunitz, Annegret [VerfasserIn] |
|---|
| | Eisterer, Wolfgang [VerfasserIn] |
|---|
| | Gaidzik, Verena [VerfasserIn] |
|---|
| | Brodowicz, Thomas [VerfasserIn] |
|---|
| | Egerer, Gerlinde [VerfasserIn] |
|---|
| | Reichardt, Peter [VerfasserIn] |
|---|
| | Hohenberger, Peter [VerfasserIn] |
|---|
| | Schuler, Markus K. [VerfasserIn] |
|---|
| Titel: | Geriatric assessment of older patients receiving Trabectedin in first-line treatment for advanced soft tissue Sarcomas |
|---|
| Titelzusatz: | the E-TRAB study from the German Interdisciplinary Sarcoma Group (GISG-13) |
|---|
| Verf.angabe: | Bernd Kasper, Daniel Pink, Christian Rothermundt, Stephan Richter, Marinela Augustin, Attila Kollar, Annegret Kunitz, Wolfgang Eisterer, Verena Gaidzik, Thomas Brodowicz, Gerlinde Egerer, Peter Reichardt, Peter Hohenberger and Markus K. Schuler |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | 28 January 2024 |
|---|
| Umfang: | 17 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Gesehen am 25.06.2024 |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 16(2024), 3, Artikel-ID 558, Seite 1-17 |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | E-TRAB was a non-interventional, prospective trial investigating the feasibility and predictive value of geriatric assessments (GA) in older STS patients treated with trabectedin as first-line therapy. Primary endpoints were overall survival (OS), quality of life and individual clinical benefit assessed by the patient-reported outcome measures QLQ-C30 and PRO-CTCAE. Further, several GA tools were applied and correlated with clinical outcomes and treatment-related toxicities. The final analyses included 69 patients from 12 German-speaking sites. The median age of patients was 78 years (range: 55 to 88). Baseline data on PROs and GA identified a diverse population of older patients with respect to their global health status, although a large proportion of them suffered from limitations, required geriatric help and had a high risk of morbidity. The Cancer and Age Research Group (CARG) score classified 38%, 29% and 23% of the patients with low, intermediate and high risks for therapy-related side effects, respectively. Median OS was 11.2 months [95%CI: 5.6; 19.4]. The study confirmed that trabectedin as first-line treatment in older patients with STS has an acceptable and manageable safety profile. Potential prognostic factors for clinical outcome and therapy-related toxicity were identified among the GA tools. Long Timed Up and Go (TUG) showed a significant correlation to OS and early death, whereas a high CARG score (>9) was associated with an increase in unplanned hospitalizations and the incidence of toxicities grade ≥ 3. |
|---|
| DOI: | doi:10.3390/cancers16030558 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.3390/cancers16030558 |
|---|
| | kostenfrei: Volltext: https://www.mdpi.com/2072-6694/16/3/558 |
|---|
| | DOI: https://doi.org/10.3390/cancers16030558 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | geriatric assessment |
|---|
| | patient-reported outcome |
|---|
| | PRO |
|---|
| | soft tissue sarcoma |
|---|
| | STS |
|---|
| | trabectedin |
|---|
| K10plus-PPN: | 1892171198 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Geriatric assessment of older patients receiving Trabectedin in first-line treatment for advanced soft tissue Sarcomas / Kasper, Bernd [VerfasserIn]; 28 January 2024 (Online-Ressource)
